golgin A6 family like 5, pseudogeneGenealiases: GOLGA6L5 · GOLGA6L8
Q-omics provides the consensus-scored GOLGA6L5P profile across patient tissues and cancer cell-line models. GOLGA6L5P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GOLGA6L5P is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, GOLGA6L5P RNA expression shows 18,278 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BRCA, and THYM as cancer lineages where GOLGA6L5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA6L5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA6L5P survival associations across molecular data types. GOLGA6L5P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA6L5P RNA expression–survival associations across cancer types. High GOLGA6L5P expression shows unfavorable associations in KIRC, UVM, STAD and PCPG, but favorable associations in UCEC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for GOLGA6L5P RNA expression.
This table summarizes GOLGA6L5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA6L5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA6L5P shows lower tumor expression in BRCA, THCA and BLCA and higher tumor expression in COAD, CHOL and LIHC. The BRCA box plot shows higher GOLGA6L5P RNA expression in normal versus tumor tissue (log2 FC = −0.582, t-test p < 0.001).
This table shows molecular features associated with GOLGA6L5P in patient tissues and cancer cell lines. In patient samples, GOLGA6L5P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
